Immunoprecise Antibodies Ltd Share Price Other OTC
Stocks
CA87588T1030
Pharmaceuticals
| Market Cap | 8.68Cr 6.3Cr 5.42Cr 5.08Cr 4.65Cr 595.23Cr 8.75Cr 60Cr 23Cr 304.18Cr 24Cr 23Cr 979.66Cr | P/E 2027 * |
-6x | P/E 2028 * | -7.85x |
|---|---|---|---|---|---|
| Enterprise Value | 8.68Cr 6.3Cr 5.42Cr 5.08Cr 4.65Cr 595.23Cr 8.75Cr 60Cr 23Cr 304.18Cr 24Cr 23Cr 979.66Cr | EV / Sales 2027 * |
4.29x | EV / Sales 2028 * | 3.49x |
| Free-Float |
90.86% | Yield 2027 * |
-
| Yield 2028 * | - |
Last Transcript : Immunoprecise Antibodies Ltd
| 1 day | -6.29% |
| Manager | Title | Age | Since |
|---|---|---|---|
Jennifer Bath
CEO | Chief Executive Officer | - | 21/02/2018 |
Richard Areglado
DFI | Director of Finance/CFO | 62 | 20/10/2025 |
Hyfte Van
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Jennifer Bath
BRD | Director/Board Member | - | 24/05/2018 |
Dirk Witters
CHM | Chairman | - | - |
Jonathan Lieber
BRD | Director/Board Member | 56 | 07/07/2025 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -6.29% | -23.22% | - | - | 6.27Cr | |
| -1.39% | +4.02% | +49.03% | +2.10% | 8.51TCr | |
| -3.68% | +1.43% | +502.14% | +32.42% | 6.02TCr | |
| +0.95% | +1.77% | -15.77% | -34.78% | 5.97TCr | |
| -1.60% | -7.63% | -3.65% | +31.05% | 5.11TCr | |
| +0.09% | -0.54% | +9.26% | +170.07% | 4.87TCr | |
| +0.73% | +1.19% | +58.27% | -15.83% | 3.29TCr | |
| -0.43% | +0.49% | +47.61% | +102.85% | 2.61TCr | |
| +0.79% | -6.56% | -2.56% | +192.31% | 2.26TCr | |
| +1.10% | -1.67% | +64.17% | +113.16% | 1.64TCr | |
| Average | -1.00% | -1.40% | +78.72% | +65.93% | 4.48TCr | |
| Weighted average by Cap. | -0.83% | -0.78% | +94.03% | +45.42% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 2.02Cr 1.47Cr 1.26Cr 1.19Cr 1.08Cr 138.8Cr 2.04Cr 14Cr 5.46Cr 71Cr 5.51Cr 5.39Cr 228.45Cr | 2.49Cr 1.81Cr 1.55Cr 1.46Cr 1.33Cr 170.7Cr 2.51Cr 17Cr 6.72Cr 87Cr 6.78Cr 6.63Cr 280.94Cr |
| Net income | -1.48Cr -1.07Cr -92.44L -86.74L -79.36L -101.56Cr -1.49Cr -10Cr -4Cr -52Cr -4.03Cr -3.95Cr -167.15Cr | -1.18Cr -85.62L -73.67L -69.13L -63.25L -81Cr -1.19Cr -8.18Cr -3.18Cr -41Cr -3.22Cr -3.15Cr -133.22Cr |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
